BIOVENTIX

Bioventix是一家专注研发用于免疫诊断、临床诊断和药物滥用检测领域的高亲和力羊单克隆抗体（SMAs）的生物技术公司。Bioventix公司生产的高亲和力抗体优于常规啮齿动物单克隆抗体，其中靶标存在于低浓度，或目标是半抗原或小分子。高亲和力SMAs的使用还赋予改善检测的灵敏度和精确度。Bioventix公司已成功开发出SMAs目标，传统的单克隆或多克隆抗体未能产生一个合适的试剂。

BACKGROUND & HISTORY

Bioventix was founded in 2003 as a biotechnology company specialising in the creation and supply of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics. However, the antibody technology laboratory and some of the staff have been based at the same location in Farnham, Surrey, UK since the early 1990s.

Focusing on the areas of clinical diagnostics and drugs of abuse testing the Company’s strategy is to identify new or existing commercial assays for which there is or may be a need for improved antibodies. We aim to provide clients with high quality SMAs that address the shortcomings of other antibodies. The high-affinity antibodies created at Bioventix have advantages over conventional rodent monoclonal antibodies where the target is present at low concentration, or where the target is a short peptide sequence or where the target is a small molecule or drug. In many assay formats, the use of high-affinity SMAs confers improved assay sensitivity and precision.

Bioventix has successfully developed SMAs to targets where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent and supplies antibodies to almost all of the global multinational immunodiagnostics companies.

The company was admitted to trade on the Alternative Investment Market (AIM) in April 2014. Since then the company has excelled in financial and share price performance.